



an Open Access Journal by MDPI

Bioactive Compounds from Marine-Derived *Aspergillus*, *Penicillium*, *Talaromyces* and *Trichoderma* Species

Guest Editors:

Dr. Rosario Nicoletti

1. Council for Agricultural Research and Economics, Research Center for Olive, Citrus and Fruit Crops, 81100 Caserta, Italy

2. Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy

Dr. Francesco Vinale

1. Dipartimento di Agraria, Università degli Studi di Napoli Federico II, 80055 Portici (NA), Italy

2. Istituto per la Protezione Sostenibile delle Piante, Consiglio Nazionale delle Ricerche (IPSP-CNR), 80055 Portici (NA), Italy

Deadline for manuscript submissions:

closed (30 June 2018)

Message from the Guest Editors

Dear Colleagues,

As the largest frontier in biological discovery, the sea represents a significant source of organisms producing novel secondary metabolites with interesting bioactivities. Within this biological material, fungi have received an increasing consideration. The constantly-increasing number of marine-derived fungi yielding valuable bioactive products makes it now appropriate to consider more organized forms of presentation to the recipient audience.

This Special Issue is specifically focused on a few genera of ascomycetous fungi. Full research papers, short notes and review articles reporting the finding and the characterization of products showing antibiotic, antitumor, antiviral, insecticidal, antimalarial, antifouling, antioxidant, plant growth-promoting and/or resistance-inducing, as well as other less exploited activities, are invited for this editorial project.

Dr. Rosario Nicoletti

Dr. Francesco Vinale

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)